NRG Clinical Trials Development Core Abstract The NRG Oncology (NRG) Clinical Trials Development Core (Core) provides the scientific leadership and infrastructure necessary to support the group's research activities and initiatives. NRG has a robust facility for clinical trials development, led by physician-investigators, statisticians, and administrative directors who possess an outstanding quantity and quality of knowledge and expertise in designing and directing complex, multicenter clinical trials that reflect the specific aims of the group. The Core works closely with the NRG's Statistics and Data Management Center, the NRG Data Monitoring Committee (DMC), and the NRG Administrative Core in soliciting, reviewing, approving, and developing prospective clinical trials. The program is committed to developing clinical trials that are congruent with NRG's and NCI's mission to implement high-quality clinical and translational trials (primarily late phase trials) in a timely manner. To that end, the Core investigators and staff work closely with NCI-CTEP, the NCTN's centralized functions (e.g., CTSU, CIRB) and the other NCTN Groups. Patient advocates and attention to diversity are included in the Core's functions. NRG's clinical trials development program is led by its Research Strategy Committee, whose members are internationally recognized chairs and vice-chairs of NRG's cancer disease site and other scientific committees who have great experience in institutional and network group research. The leaders and core members of these committees understand the importance of protocol development, new investigator training/mentorship, trial conduct, completion and timely analysis and publication of study results. These physician investigators and the Core administrative staff are well aligned with the overall mission of the NCTN and the continued success of NRG Oncology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180868-06
Application #
9627155
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-04-16
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Nrg Oncology Foundation, Inc.
Department
Type
DUNS #
078695317
City
Philadelphia
State
PA
Country
United States
Zip Code
19103
Geyer Jr, Charles E; Tang, Gong; Mamounas, Eleftherios P et al. (2018) 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer 4:37
Small Jr, William; James, Jennifer L; Moore, Timothy D et al. (2018) Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123. Am J Clin Oncol 41:396-401
Matulonis, Ursula A; Sill, Michael W; Makker, Vicky et al. (2018) A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol :
Bell, Erica H; Zhang, Peixin; Fisher, Barbara J et al. (2018) Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. JAMA Oncol 4:1405-1409
Lukka, Himanshu R; Pugh, Stephanie L; Bruner, Deborah W et al. (2018) Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys 102:287-295
Ahmed, Amina; Deng, Wei; Tew, William et al. (2018) Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol 150:300-305
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Bandos, Hanna; Melnikow, Joy; Rivera, Donna R et al. (2018) Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst 110:
Coen, John J; Zhang, Peixin; Saylor, Philip J et al. (2018) Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol :JCO1800537
Crook, Juanita M; Zhang, Peixin; Pisansky, Thomas M et al. (2018) A Prospective Phase II Trial of Trans-perineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiotherapy (NRG Oncology/RTOG -0526). Int J Radiat Oncol Biol Phys :

Showing the most recent 10 out of 357 publications